Chugai and Takeda to Join a Clinical Collaboration for Global Phase III Studies for the Combination Therapy with Multiple Tumor Types in Japan

- Subsequent to a joint clinical research agreement between Roche and Exelixis, Chugai and Takeda have decided to study Tecentriq® (atezolizumab) and CABOMETYX® (cabozantinib) combination therapy in Japan
- The three global phase III CONTACT studies are currently ongoing to investigate the combination of atezolizumab and cabozantinib in multiple cancer types

TOKYO – September 10, 2020 – Chugai Pharmaceutical Co., Ltd. (Chugai, TSE: 4519) and Takeda Pharmaceutical Co., Ltd. (Takeda, TSE:4502/NYSE:TAK) have decided to study the combination of Tecentriq® (atezolizumab), an engineered anti-PD-L1 monoclonal antibody and CABOMETYX® (cabozantinib), a tyrosine kinase inhibitor, in Japan.

Subsequent to a joint clinical research agreement between Roche and Exelixis and in conjunction with certain rights granted in Japan, Chugai and Takeda will study atezolizumab and cabozantinib combination therapy in Japan. The three global phase III CONTACT studies are ongoing to investigate the combination of atezolizumab and cabozantinib as a potential new treatment option in multiple tumor types, and Chugai and Takeda are planning to join in supporting these studies in Japan.

About Tecentriq
Tecentriq is an immune checkpoint inhibitor targeting PD-L1 which is a protein expressed on tumor cells and tumor-infiltrating immune cells. PD-L1 blocks T-cell activity by binding with PD-1 and B7.1 receptors on T-cell surface. By inhibiting PD-L1, Tecentriq may enable the activation of T-cells and boost immune response against cancer cells.

In Japan, Tecentriq has been approved as a treatment of unresectable advanced/metastatic non-small cell lung cancer, extended-stage small cell lung cancer and PD-L1-positive inoperable or metastatic triple negative breast cancer. In addition, a supplemental application of Tecentriq in combination with Avastin® (bevacizumab) was submitted for the treatment of unresectable metastatic hepatocellular carcinoma to the Ministry of Health, Labour and Welfare (MHLW) and was designated as priority review by the MHLW.

About CABOMETYX
In the U.S., CABOMETYX tablets are approved for the treatment of patients with advanced renal cell carcinoma (RCC) and for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. CABOMETYX tablets have also received regulatory approvals in the European Union and additional countries and regions worldwide. In Japan, the product was approved for the treatment of curatively unresectable or metastatic RCC as
CABOMETYX® tablets 20mg and 60mg in March 2020 by the Ministry of Health, Labor and Welfare and launched in May 2020. In addition, a supplemental application was submitted in Japan for the treatment of unresectable HCC that has progressed following chemotherapy in January 2020.

About Chugai
Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs. Additional information is available at https://www.chugai-pharm.co.jp/english/.

About Takeda
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit https://www.takeda.com.

About the Takeda and Exelixis Collaboration
In January 2017, Takeda entered into a collaboration agreement with Exelixis for the commercialization and further clinical development of cabozantinib for all future indications in Japan. Exelixis retains exclusive rights to develop and commercialize cabozantinib in the United States and has licensed exclusive rights to commercialize cabozantinib outside of the United States and Japan to Ipsen Pharma SAS.

Tecentriq® (atezolizumab) is a registered trademark of F. Hoffman-La Roche AG

CABOMETYX® (cabozantinib) is a registered trademark of Exelixis, Inc.

Contacts:
Chugai Pharmaceutical Co., Ltd.
Corporate Communications Dept.
Media Relations Group
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp

Investor Relations Group
Tel: +81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp

Takeda Pharmaceutical Co., Ltd.
JPBU Communications
Asa Hayashi
Tel: +81 (0) 3-3278-2519
E-mail: asa.hayashi@takeda.com